Form 4: Palvella Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Wes Kaupinen, President and CEO of Palvella Therapeutics, acquires 243,831 non-qualified stock options.
Summary
- On February 5, 2025, Wes Kaupinen, President and CEO of Palvella Therapeutics, acquired 243,831 non-qualified stock options.
- The options have an exercise price of $14.76.
- The options vest in equal monthly tranches over 48 months.
- The options expire on February 5, 2035.
Sentiment
Score: 5
Explanation: The document simply reports a routine transaction of stock options, so the sentiment is neutral.
Industry Context
This is a standard practice for incentivizing and retaining key executives in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of transaction: Wes Kaupinen acquired stock options |
| 02/07/2025 | Date of Form 4 filing |
| 02/05/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.